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Abstract
Background: Esophageal tumors generally bear a poor prognosis. Radical surgery is generally the
only curative method available but is not feasible in the majority of patients; palliative therapy with
stent placement is generally performed. It has been demonstrated that High Intensity Ultrasound
can induce rapid, complete and well-defined coagulation necrosis. Thus, for the treatment of
esophageal tumors, we have designed an ultrasound applicator that uses an intraluminal approach
to fill up this therapeutic gap.
Methods: Thermal ablation is performed with water-cooled ultrasound transducers operating at
a frequency of 10 MHz. Single lesions extend from the transducer surface up to 10 mm in depth
when applying an intensity of 14 W/cm2 for 10s. A lumen inside the therapy applicator provides
path for an endoscopic ultrasound imaging probe operating at a frequency of 12 MHz. The
mechanical rotation of the applicator around its axis enables treatment of sectorial or cylindrical
volumes. This method is thus particularly suitable for esophageal tumors that may develop only on
a portion of the esophageal circumference. Previous experiments were conducted from bench to
in vivo studies on pig esophagi.
Results: Here we report clinical results obtained on four patients included in a pilot study. The
treatment of esophageal tumors was performed under fluoroscopic guidance and ultrasound
imaging. Objective tumor response was obtained in all cases and a complete necrosis of a tumor
was obtained in one case. All patients recovered uneventfully and dysphagia improved significantly
within 15 days, allowing for resuming a solid diet in three cases.
Conclusion: This clinical work demonstrated the efficacy of intraluminal high intensity ultrasound
therapy for local tumor destruction in the esophagus.
Background
Most occurrences of esophageal tumors are not amenable
to curative resection because of the extent of the tumor at
diagnosis and the presence of a comorbid condition.
Chemotherapy and/or radiochemotherapy have not dem-
onstrated any survival advantage so far. In this context,
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new methods for local tumor destruction, such as the use
of physical agents, have raised interest. For example,
endoscopic clearance of the esophagus is already routine
with laser photocoagulation [1,2] being widespread
although its action remains superficial and several ses-
sions are generally needed to achieve symptomatic
improvement. Indeed esophageal tumors, which develop
inside the circumference of the lumen, are very difficult to
treat by physical agents for two reasons. They are some-
times sector-based and the tumor thickness can vary sig-
nificantly from one point to another (three millimeters to
12 mm in most cases). Thus, for this form of cancer, a
minimally invasive local treatment, leading to an imme-
diate, deep and complete destruction of the targeted tis-
sues, could be curative in the earliest-detected cases. If the
tumor has reached a metastatic stage, the treatment could
be envisaged as a palliative strategy to delay the use of
stents and increase the median survival time. Among the
heating modalities for therapeutic thermal ablation, tissue
coagulation by high intensity ultrasound is a well-estab-
lished method of tumor treatment [3-6]. Treatments by
ultrasound are well-delimited; damages to surrounding
tissues are minimal. Excellent results have been obtained
(both experimentally and clinically) in inducing homoge-
neous and reproducible tumor destruction by thermal
coagulation necrosis. Recently, several authors have sug-
gested using miniaturized applicators for therapeutic
ultrasound [7-9], which makes it an approach that is par-
ticularly appropriate for carcinoma of the esophageal
ducts.
In this study, a plane transducer was used to generate sin-
gle parallelepiped-shaped lesions in front of the emitting
face. Since the ultrasonic beam does not diverge in the
near field, the pressure drop along the ultrasonic axis is
only dependent on the energy attenuation in tissues[10].
Each single lesion can be induced in 10 seconds to a depth
up to 16 mm, and with almost no perfusion-dependence
[11]. Furthermore, by rotating the applicator around its
axis after each ultrasound exposure, a sector-based or
cylindrical volume can be coagulated. Ex vivo experiments
conducted on pig liver demonstrated the ability of the
applicator to generate any angular sector-based lesion
with a good angular accuracy by rotating the transducer
and juxtaposing single lesions. The dimensions of the
cylindrical lesions were associated with the exposure con-
ditions. In addition, preliminary experiments conducted
in vivo on pig esophagi have shown the feasibility of the
treatment [11,12] and allowed the determination of the
thermal dose that can be administered to different regions
of the esophagus. In this paper we describe an open pilot
trial which was conducted between Sept, 2002 and Nov,
2004 on four patients with adenocarcinoma or squamous
cell carcinoma. The aim of this study was to investigate the
safety and feasibility of intraluminal high intensity ultra-
sound for the treatment of esophageal tumors.
Methods
Ultrasound equipment
The head of the applicator is made of brass and round-
shaped to permit transesophageal application without
risk of injury (Fig. 1). The ultrasound emitter is a 15 × 8
mm2 piezoceramic plane transducer (Quartz & Silice, P7-
62, Nemours, France) which operates at 10.4 MHz. This
air-backed transducer was sealed with epoxy resin (Emer-
son & Cuming, Stycast 2651, Westerlo, Belgium) to ensure
the applicator was watertight. The rotation of the applica-
tor is controlled remotely with negligible angular loss
using an 80-cm long, 10-mm outer diameter (OD), flexi-
ble metallic shaft. A biocompatible envelope (1.3 mm
thick) covers this metallic shaft. This envelope conforms
to medical device safety requirements USP VI (U.S. Phar-
macopoeia, class VI). Connections for the transducer sup-
ply are done with a PVC casing attached on the opposite
end of the applicator. This casing is mounted on an UR
100 microcontrol unit (Microcontrol, Evry, France) to
monitor the rotation of the applicator. Electrical connec-
tions were realised via a miniaturised 50-ohms coaxial
cable that was 80-cm long with a 0.9-mm OD. A tube (1-
mm OD) over the whole length of the applicator is for
holding a guide wire previously introduced in the esopha-
gus. The active part of the applicator was covered with a
65-μm thick latex balloon attached using watertight seals.
This envelope attenuated the ultrasound pressure by
about 9% and was inflated with degassed water to provide
acoustic coupling between the transducer and the tissues.
This envelope can be inflated via a syringe connected to
the tank. During treatments, the transducer was cooled
using a continuous flow of degassed water at room tem-
perature (25°C) at a rate of 0.2 L/min. A peristaltic Mas-
terflex pump (L/S model 7518-60, Cole-Parmer
Instruments Co., Chicago, IL, USA) drove the water
around a closed cooling circuit and through a 1-liter
watertight tank of degassed water at room temperature.
The treatment is monitored using an ultrasound imaging
probe. A tube inside the applicator provides path for an
UM2R ultrasound imaging probe (Olympus, Japan)
which goes through the therapy applicator and perform a
visualisation of the tissues in front of the therapy trans-
ducer (Fig. 2). The ultrasound imaging probe operates at
a frequency of 12 MHz. In order to avoided damages to
the imaging probe, it slides inside the applicator during
high intensity ultrasound exposures.
The electrical power was delivered in continuous mode by
a Kalmus model 150 CF power amplifier (Engineering
International, Woodinville, WA, USA) driven by a Hameg
HM8131 sinusoidal wave generator (Hameg, Frankfurt,
Germany). Directional power meter (wattmeter/reflec-Journal of Translational Medicine 2008, 6:28 http://www.translational-medicine.com/content/6/1/28
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tometer (Rohde & Schwarz, Munich, Germany) fitted with
a bidirectional coupling device probe (NAP Z7, Rohde &
Schwarz, Munich, Germany) were inserted into the line
between the amplifier output and the ultrasound applica-
tor to determine the incident and reflected electrical
power. The generator was controlled by a timer, which
enabled emissions to be triggered manually and cut off
automatically at the end of the desired exposure time. A
radiation force balance, to the design of Hill [13], was
used to measure the total acoustic power output of the
ultrasound beam in degassed water at 21°C. An electro-
acoustic efficiency of 61% at 10.4 MHz was measured.
Patients
Previous animal experiments [11,12] led to an open pilot
trial which was conducted between Sept, 2002 and Nov,
2004, after institutional review board approval from
INSERM, Paris. Informed consent for the study was
obtained from all patients and conformed to world med-
ical association declaration of Helsinki Ethical Principles
for Medical Research Involving Human Subjects, 2004.
Criteria for inclusion were the presence of a histologically
proven cancer of the esophagus, of any T, N and M stage,
without invasion of the tracheo-bronchial tract on CT-
scan or endoscopic sonography (EUS), considered non
operable as a consequence of local or distant extent or of
associated comorbidities. Patients with tracheo-bronchial
invasion, tracheo-esophageal fistula, patients with an
American Society of Anesthesiology (ASA) grade > 3 or
Karnofsky index < 50%, patients with major coagulation
impairment or bearing an esophageal stent were excluded.
All procedures were undertaken under general anesthesia
with airway intubation, as most endoscopic therapeutic
procedures on the esophagus and also because it was a
pilot study with relatively lengthy procedures. Pain assess-
ment was done as usual in the post-interventional ward
with opioid titration if necessary. It was planned to
include 5 patients in this preliminary trial. The study end-
points were the feasibility of the treatment (with empha-
sis on the tumor visualization and position control during
treatment) and the presence of effective tumor destruction
in accordance with the visible tumor localization.
Intraluminal ultrasound applicator Figure 1
Intraluminal ultrasound applicator. (a) Schematic diagram of the applicator. (b) US device for the treatment of esophageal 
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Improvement in comfort (dysphagia visual scale graded
0–5) and quality of food intake, as well as undesirable
side effects were also noted as secondary endpoints. The
treatment was planned as a one session therapy, with a
possibility of repeated sessions in case of initial positive
but partial result.
Ultrasound treatments
Treatment was performed with the rotating transducer
described above guided on a 0.035" guidewire, after boug-
ienage when necessary (9 or 11 mm bougie). Gross posi-
tioning of the transducer was achieved under fluoroscopy
after lipiodol injection in the upper and lower ends of the
tumor as assessed by endoscopy, and positioning of
metallic clips on the patient's skin (Fig. 3). Fine position-
ing and sectorial imaging, prior to and during treatment
was achieved by use of the 12 MHz ultrasound imaging
probe introduced in the dedicated channel of the thera-
peutic ultrasound applicator (Fig. 4). After confirming
that the applicator was in correct position, the acoustic
intensity at the surface of the transducer was adjusted (12
to 14 W/cm2) according to the thickness of the tumor. The
duration of each exposure was 10 seconds. After each sin-
gle lesion, the device was rotated 18 degrees around its
axis, this motion being controlled manually from the
external end of the device by means of a micrometer
screw. These exposure conditions come from preliminary
studies [11]. High intensity US application was circumfer-
ential or sectorial depending on EUS miniprobe and
endoscopic appearance. After completion of a circumfer-
ential (20 single lesions) or sectorial application, the
ultrasound applicator was moved within the stricture
under fluoroscopy so as to create overlapping treatment
rings. These maneuvers were repeated until the entire
length of the stricture was treated.
Follow-up
Follow-up was based on esophagoscopy with biopsies 8
days, 1 month and 3 months after therapy. Patients
included in radiochemotherapy protocols underwent oth-
erwise usual follow-up. Five patients have been included
but only 4 have been treated with ultrasound. One patient
included with a tumor of the esophagus at the level of the
oro-pharyngeal junction was found to have a tracheo-
Head of the intraluminal high intensity ultrasound applicator Figure 2
Head of the intraluminal high intensity ultrasound 
applicator. The ultrasound imaging probe is in front of the 
therapeutic transducer to image the region of interest.
Gross positioning of the therapeutic ultrasound applicator Figure 3
Gross positioning of the therapeutic ultrasound 
applicator. The therapeutic ultrasound applicator was 
placed in the esophagus under fluoroscopy after positioning 
metallic clips on the patient's skin.
Sonogram of an esophageal tumor obtained during treatment Figure 4
Sonogram of an esophageal tumor obtained during 
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esophageal fistula and was excluded. The other 4 patients
are described in the results section and in table 1.
Results
Three patients (patients 1, 2 and 4) had squamous cell car-
cinoma (SCC) and one patient (patient 3) had adenocar-
cinoma (AC). In one case we found a double localization
of a locally advanced SCC. Tumors were completely cir-
cumferential in 4 cases and sector-based (110° and 180°)
in two cases. One patient (patient 1) was found to have a
SCC of the median 1/3 of the oesophagus extending over
45 mm in length; the stricture was circumferential over
the distal 30 mm and hemi-circumferential over the prox-
imal 15 mm. Treatment was feasible in all patients, the
main limitation encountered was the quality of treatment
guidance using EUS miniprobe and the quality of the ther-
apeutic applicator rotation. Tumor imaging was subopti-
mal by EUS miniprobe due to artifacts by multiple
reflections on the therapeutic transducer and the presence
of the balloon. In these cases, the contrast between tumors
and normal tissues was less obvious when the miniprobe
was inserted inside the therapeutic applicator. Addition-
ally, the rotation of the applicator was not fully satisfac-
tory, with fits and starts instead of a smooth rotation, in 2
out of the 4 patients treated. Therefore, depending of the
quality of the probe rotation, the number of ultrasound
exposures was adjusted during the procedure according to
probe positioning visualized on ultrasound images.
Before the treatment, probe positioning in the stricture
using fluoroscopy and EUS miniprobe was accurate and
satisfactory in all cases. On average 25 ultrasound expo-
sures were performed to treat circumferential tumors, 8
and 12 ultrasound exposures were performed for the 110°
and 180° tumors respectively. In three cases (patients 1, 3
and 4) treatment was applied on several levels (two to
three) depending on tumor length. The mean specific pro-
cedure duration, including set-up of equipment and US
application was 37 ± 10 minutes (range 20 – 51 minutes).
Objective tumor response was obtained in all cases. All
patients recovered uneventfully and dysphagia improved
significantly within 15 days, allowing for resuming a solid
diet in three cases. Overall results are summarized in table
2.
Patient 1
An 80-year old man presenting with complete dysphagia
was found to have a squamous cell carcinoma (SCC) of
the median 1/3 of the oesophagus extending over 45 mm
in length; the stricture was circumferential over the distal
30 mm and hemi-circumferential over the proximal 15
mm. The estimated tumor transversal diameter was 30
mm on CT-scan and EUS, and the TNM stage was
usT3N1M0. Severe comorbidities (vascular and pulmo-
nary) were found. Upper endoscopy revealed an associ-
ated adenocarcinoma of the antrum, which was classified
as T1N0. Ultrasound was applied on 2 levels over 360°
and on the proximal level over 180°, under EUS mini-
probe control. The patient recovered uneventfully. Eight
days after the treatment, tumor necrosis was observed on
the whole length of the tumor, except at the proximal part
where necrosis appeared to be incomplete. A second focus
of incomplete necrosis was noted on 5 mm in the centre
of the tumor. The necrosis was pushed distally with the
endoscope and the stricture was subsequently passed eas-
ily without need for further dilation (Fig. 5). Dysphagia
improved considerably during the following 2 weeks,
allowing for solid food intake, but recurred at 4 weeks:
control upper endoscopy at 1 month showed an obstruc-
tive nodule at the upper part of the tumor, while the more
distal part remained persistently patent. Despite a partial
efficacy of the US therapy, a second session was declined
and radiochemotherapy was started, along with the inser-
tion of a self-expandable covered stent. Control endos-
copy at four months showed no tumor progression and
the patient presented no dysphagia, with a patent stent.
Table 1: Characteristics of individual patients. 
No. Gender Age Tumor type TNM stage Stricture C/L/
T
Number of 
US sessions
Other 
treatments
Dysphagia 
Improvement
M1 status M3 status Survival
1 M 80 SCC T3N1M0 360°/30/6 
180°/15/6
1 5FU/CDDP 5 > 1 PR Clin: good 
Obstructive 
nodule Stent 
require
No tumor 
progression 
Clin: good No 
dysphagia
>4 mo
2 M 55 SCC T1N0 110°/10/7 
360°/9/9
3 5FU/CDDP 3 > 0 CR, proximal 
tumorPR, 
distal 
tumorClin: 
goodNo 
dysphagia
PRClin: poor, 
deteriorating 
general 
conditionRecu
rrent 
dysphagia
6 mo
3 M 83 AC T3N2M1 360°/30/12 1 5FU 5 > 2 3 wk
4 F 86 SCC T3NxM0 360°/20/7–12 1 5 > 2 PRClin: 
poorWeight 
loss (2 kg)
3 mo
SCC, squamous cell carcinoma; AC, adenocarcinoma; TNM, tumor, node, metastasis; C/L/T, circumference/length/thickness of tumor (mm); 5FU, 
fluorouracil; CDDP, cisplatinum; M1, M3, 1 and 3 months after treatment; clin, clinical status; PR, partial response; CR, complete response; US, 
ultrasound.Journal of Translational Medicine 2008, 6:28 http://www.translational-medicine.com/content/6/1/28
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Patient 2
A 55 year-old man had previously undergone radiochem-
otherapy (5FU-CDDP-based) for a double localization of
a locally advanced SCC of the upper and median 1/3 of
the oesophagus. A complete response had been estab-
lished in 2002. One year later, follow-up endoscopy
revealed recurrences on both initial sites, without signifi-
cant symptoms. On EUS, the upper tumor was graded
T1N0 and the lower tumor appeared to infiltrate the mus-
cularis propria, without evidence of lymph node involve-
Patient 1 Figure 5
Patient 1. Tumor necrosis was observed on the whole length of the tumor, except at the proximal part where necrosis 
appeared to be incomplete. (a) Control endoscopy 8 days after the treatment. The necrosis was pushed distally with the endo-
scope. T, remaining tumor. N, Tumor necrosis. (b) EUS examination 8 days after the treatment.
Table 2: Summary of treatment results
1 week 1 month 3 months
Patient 1 Biopsies Positive in obstructive nodule Positive in obstructive nodule Positive in obstructive 
nodule
Stricture reduction Obstruction: 10% Obstructive nodule at the upper 
part of the tumor
Obstructive nodule at the 
upper part of the tumor
Endoscopic aspect Necrosis on the whole length 
of the tumor
Necrosis on 75% of the tumor No tumor progression
Patient 2 After the 3rd 
session of ultrasound
Biopsies Positive in non necrotic areas Positive in non necrotic areas Not done
Stricture reduction No obstruction No obstruction
Endoscopic aspect Proximal tumor: Complete 
necrosisDistal tumor: 90% 
necrosed
Proximal tumor: No stenosis, 
complete necrosisDistal tumor: 
Infiltrating non-stenotic aspect
Patient 3 Biopsies Control endoscopy was 
contra-indicatedNo 
dysphagia
Stricture reduction
Endoscopic aspect
Patient 4 Biopsies Not documented Not documented Negative
Stricture reduction Obstruction: 90% → 50%
Length: 2 cm → 1 cm
Obstruction: 50%
Length: 1 cm
Obstruction: 50% → 70%
Length: 1 cm
Endoscopic aspect Large necrotic area on the 
whole length of the tumor
Large necrotic area on the whole 
length of the tumor
Large necrotic area on the 
whole length of the tumorJournal of Translational Medicine 2008, 6:28 http://www.translational-medicine.com/content/6/1/28
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ment. Both tumors did not exceed 4 mm in thickness. It
was decided to attempt ultrasound therapy. A first treat-
ment session was undertaken with decreased power out-
put in order to prevent transmural necrosis and possible
fistula. At control endoscopy at 8 days, there was no evi-
dence of tissue ablation and biopsies showed persistence
of carcinoma cells. A second treatment session was subse-
quently proposed, with the same treatment parameters.
The control endoscopy 10 days after this second treatment
demonstrated non significant change and still positive
biopsies. Three months later, the patient presented with
mild dysphagia and a moderate weight loss. On the
patient's request, a 3rd treatment session was decided;
since the tumor thickness had increased in the meantime
to reach a maximum of 7 mm, usual treatment parameters
were applied. Recovery was uneventful, a mild cervical
pain requiring 2 g paracetamol IBD during 3 days was
noted, and dysphagia disappeared completely within 10
days, along with an improvement in the patient's per-
formance status. Control endoscopy at 10 days showed a
complete necrosis of the proximal lesion (Fig. 6) and an
estimated 90% necrosis of the more distal one were
achieved after three ultrasound treatment sessions. At 1
month, the patient maintained the same performance sta-
tus (Karnofsky 90%), had a steady weight and no dys-
phagia. Endoscopy showed no stenosis, an infiltrating,
non-stenotic aspect of the distal lesion and a nearly com-
plete regression of the proximal lesion. Two months later
(3 months after the third ultrasound session), the patient
presented with recurrent dysphagia and deteriorating gen-
eral condition. He was admitted in a primary referral cen-
tre, where no endoscopy was done, and a complementary
radiotherapy was discussed. During this hospital stay, a
sepsis developed with a septic shock and coma. Blood cul-
tures and cephalo-rachidian fluid were positive for E. coli
sp., leading to the diagnosis of meningo-encephalitis sec-
ondary to a septicaemia of unknown origin.
Patient 3
An 83 year-old man presenting with dysphagia and a
major weight loss (-15 kg) was diagnosed to have an ade-
nocarcinoma of the distal oesophagus developed on Bar-
rett's oesophagus. The tumor was staged usT3N1 on EUS
and N2M1 on CT-scan (cervical lymph nodes and multi-
ple liver metastases). The oesophageal stricture was meas-
ured at 30 mm in length and 12 mm in thickness.
Additionally, the patient presented a stenosis of benign
appearance of the upper 1/3 of the oesophagus. Although
no specific cause was demonstrated to explain this second
stenosis, a mediastinal tumor extent was suspected. In
view of the poor prognosis, the strategy included an endo-
scopic stenting of the upper oesophageal stenosis, an oral
chemotherapy based on oral 5FU and an ultrasound ther-
apy of the lower oesophageal stricture with the aim of
comfort improvement. The ultrasound treatment was per-
formed on 2 levels of the ultrasound transducer with a sat-
isfactory visualization of the tumor and an oesophageal
stent was implanted. The patient recovered uneventfully
and his dysphagia improved significantly within 10 days,
allowing for resuming a solid diet. However, the perform-
ance status decreased continuously with the progressive
development of jaundice due to the hepatic metastases.
Subsequently, the control endoscopy was contra-indi-
cated and the patient died 3 weeks after ultrasound ther-
apy.
Patient 2 Figure 6
Patient 2. Control endoscopy of the esophageal tumor. (a) before and (b) 10 days after the treatment.Journal of Translational Medicine 2008, 6:28 http://www.translational-medicine.com/content/6/1/28
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Patient 4
An 86 year-old woman presenting with severe dysphagia
and a weight loss of 14kg was found to have an oesopha-
geal SCC of the lower 1/3 of the oesophagus extending
over 20 mm in length and 7 to 12 mm in thickness (25
mm in overall diameter). The tumor was staged usT3Nx
on EUS and M0 on CT-scan. Due to her old age,
oesophagectomy was not a reasonable option and US was
proposed for palliation as the sole therapeutic method.
The treatment was achieved over 2 levels of the US trans-
ducer. The patient recovered uneventfully. After 8 days,
the dysphagia score regressed from 5 to 2 and the follow-
up endoscopy demonstrated a large necrotic area on the
whole length of the tumor, predominantly in the centre of
the lesion, and a regression of the percentage of oesopha-
geal obstruction from 90% to an estimated 50%, with a
stricture length reduced from 2 to 1 cm. At 1 month, the
dysphagia score was identical, the patient had lost another
2 kg, and the endoscopic observations were unchanged as
compared to the first follow-up endoscopy. After 3
months, the patient's general condition remained fair, but
she had lost another 2 kg, her dysphagia had increased
from a score of 2 to 3, allowing only a soft diet and the
endoscopy showed an increase in the degree of the stric-
ture estimated at 70% without any increase in length (10
mm as previously). Biopsies were negative. Bougienage
was done up to 13 mm without further stenting.
Discussion
The efficacy of local tumor destruction by high-intensity
ultrasound therapy has been has been established for dec-
ades, both experimentally and clinically [14,4,3]. Intralu-
minal US therapy with a plane rotating transducer is a new
application that is particularly suitable for the tumors of
the digestive tracts. In addition, the rotation of the trans-
ducer allows for treatment of specific segments of the cir-
cumference of a hollow organ, which makes the method
particularly suitable for noncircumferential esophageal
tumors.
Prior to clinical studies, encouraging experimental results
have been achieved with intraluminal flat transducers in
pigs which is an ideal animal to study the different treat-
ment options available for the treatment of esophageal
tumor, in view of its size and physiology similar to
humans. However, there is no established tumor model in
pigs due to the absence of porcine liver tumor cell lines
which can be used to create esophageal tumors in the pig.
Nevertheless, the efficacy of HIFU on tumors as been
demonstrated with many clinical studies and is not
dependent of the soft tissues that are sonicated [14]. In
addition, the experimental histological studies have
shown that the lesions created in pigs were homogeneous
[11] and our experimental results in pigs were considered
to be applicable to humans. The present clinical series
provides further evidence of the feasibility and patient tol-
erance of the method. The US treatment was well tolerated
by all patients.
The intraluminal US applicator was developed for direct
insertion in the esophagus and over a 0.035-inch
guidewire. The applicator was in all cases easily exchanged
over the guidewire and its insertion within the esophagus
was also feasible in all patients, as was transducer posi-
tioning under fluoroscopic guidance. The system and
techniques developed free the endoscopist's hands for the
purpose of controlling the actual application of the US
energy.
The clinical pilot trial was planned to be continued if the
first results had been enough satisfactory. We observed
several limitations, related in particular to the rotation of
the applicator. Both of these 2 criteria were found unsatis-
factory in 2 out of the 4 patients actually treated. This is
explained by a reduced image quality of the US miniprobe
when introduced into the applicator, which is worsened
by the presence of the balloon. This is responsible for
impairment in tumor imaging and subsequent transversal
positioning in case of sectorial tumor infiltration. The
uneven rotation of the probe was due to frictions over the
applicator induced by the presence of tumor tissue, thus
precluding a smooth and accurate transducer rotation.
None of these factors could have been foreseen from pre-
clinical studies, since there was no animal model of
esophageal tumor available. Excess deep coagulation
necrosis is expected to potentially induce mediastinal per-
foration. This complication was not observed in this pilot
study, despite inadequate imaging of the tumor and sur-
roundings in two cases. Indeed, a complete in-depth
destruction of tumors infiltrating the muscularis propria
might create esophageal perforation and mediatinal or
oeso-tracheal fistulae, depending on tumor location.
However, this hazard is probably less problematic com-
pared with destruction methods such as radiofrequency or
bipolar electrosurgery in which coagulation is both less
rapid and less accurate. Ultrasound ablation induces a
progressive necrosis which allows enough time for inflam-
mation and sclerosis to develop and form an inflamma-
tory barrier against sepsis. This has been previously
demonstrated in preliminary short-term animal experi-
ments [11].
Patients with radiochemotherapy treatments were
included in this study. Nevertheless, confusion between
radiation and ultrasound-induced necrosis was unlikely
since patients did not undergo radiotherapy during the
same period as ultrasound. In patients receiving chemo-
therapy, tumor response does not translate into brutal
necrosis, but rather into progressive tissular thaw. Addi-
tionally, an early endoscopic control was done 8 days afterJournal of Translational Medicine 2008, 6:28 http://www.translational-medicine.com/content/6/1/28
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ultrasound exposure has clearly demonstrated the sharply
delineated US-induced necrosis.
Nevertheless, this clinical study has shown that the treat-
ment was feasible and induced tumor necrosis as well as a
significant and relatively rapid symptomatic improve-
ment in these severely ill patients. We have decided to
resume these clinical studies as soon as the above men-
tioned problems will be appropriately addressed. Our
main goals are now to develop multitransducer applica-
tors which can be operated without any mechanical rota-
tion, once positioned longitudinally, and to prefer
magnetic resonance imaging to ultrasound diagnostic to
achieve tumor imaging [15]. Additionally, long-term fol-
low-up studies are needed to assess late treatment results
in patients who have small tumors without evidence of
regional or distant extension.
Future studies will need to determine whether US applica-
tion is only a new palliative method, perhaps abolishing
the need for stents in some cases, or whether it can also be
curative in selected high-risk patients or those with local-
ized tumors. Ultrasound therapy can be discussed in a
neo-adjuvant setting, in order to reduce the tumor bulk
and reinforce the tumor response before surgery, as a com-
plement to RT-CT. However, one should be aware of the
potentially deleterious mediastinal inflammation which
might make resection difficult or impossible. Finally, the
indications most likely to be of interest in esophageal can-
cer are listed as follows:
-superficial tumors with important lateral spread (longitu-
dinal and circumferential) precluding endoscopic resec-
tion by current methods (endoscopic mucosal resection
and endoscopic submucosal dissection).
-palliation in locally advanced or metastatic tumors for
desobstruction and as a complement to chemotherapy.
-in combination with or as an alternative to RT-CT in cases
of recurrence after surgery or RT-CT, resistance to RT-CT or
failed resection (tumor not reseceted).
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